Theravance Biopharma TBPH Payments For Purchase Of Derivative Instrument Investing Activities
Payments For Purchase Of Derivative Instrument Investing Activities at other companies
Other financials
Where this comes from
Reported directly by Theravance Biopharma in its filing.
Tagged under the XBRL concept tbph:PaymentsForPurchaseOfDerivativeInstrumentInvestingActivities.
The official record: Theravance Biopharma’s 10-K, filed March 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Theravance Biopharma's payments for purchase of derivative instrument investing activities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Theravance Biopharma's payments for purchase of derivative instrument investing activities?
- Theravance Biopharma (TBPH) reported payments for purchase of derivative instrument investing activities of $573K in Q4 2024.
- What does payments for purchase of derivative instrument investing activities mean?
- This measures cash outflows used to acquire derivative financial instruments, typically for hedging interest rate, currency, or market risks. It reflects the company's strategy for managing financial volatility and protecting the balance sheet. High levels of activity here indicate an active risk management program to mitigate exposure to external market fluctuations.